

# Scientific Report



**Josep Carreras**  
LEUKAEMIA  
Research Institute

### **Headquarters**

C/ Muntaner, 383 3r. 08021  
Barcelona  
Tel. (+34) 93 414 55 66

For any matter concerning this report  
please contact:  
[comunicacio@carrerasresearch.org](mailto:comunicacio@carrerasresearch.org)


The report can also be downloaded  
from:  
<http://www.carrerasresearch.org>

### **Publisher, layout and typesetting**

Josep Carreras Leukaemia Research  
Institute

### **Photography**

Photographic archives of the Josep  
Carreras Leukaemia Foundation and  
the Josep Carreras Leukaemia  
Research Institute



“The Institute's three campuses are surrounded by excellent scientific and health service facilities. It is the aim of our project to enhance, integrate, share and strengthen this already excellent situation even more, and this is already being done at the management level, by simplifying and sharing structures, and at the scientific level, by integrating cross-section and multi-site services to avoid unnecessary duplication. Everything we do is focused on making leukaemia and other malignant blood diseases 100% curable one day.”

Josep Carreras  
President of the Board of Trustees  
Josep Carreras Leukaemia Research Institute  
(IJC)



# Contents



---

## About us

Welcome  
Who we are  
What we research  
Mission, vision and values  
Schematic model

## Our team

Governing bodies  
Organisational chart  
Human resources

## Financial data

Income statement  
Balance sheet  
Fundraising

---

## Scientific activities

Research groups  
Research projects  
Technology platforms  
Clinical trials  
Innovation and transferability

## Scientific production

Publications  
Impact factors

## Training activities

Graduate and post-graduate  
Theses read  
Seminars and sessions  
Courses and congresses

---

## Cooperation

Agreements  
Institutions involved


## Communication

Scientific dissemination

## Upcoming challenges

New building  
SUMA agreement





# About us



# Welcome



Once again the IJC's annual report is testimony to the excellent research being carried out at the three Josep Carreras campuses. Our congratulations are due, therefore, to everyone for their magnificent work and scientific rigour.

2015 was a year in which progress was made in the fight against leukaemia. It was a year of combined scientific efforts, continuing cooperation and commitment to society.

And our centre is seeing how its facilities are expanding with the new building in Badalona, made possible by funding from the Josep Carreras Foundation.

Highlights of the IJC's leadership are the construction of the new building in Badalona and the agreements about the SUMA project between the Germans Trias Institute (IGTP) and the Institute for Predictive and Personalised Cancer Medicine (IMPPC).

With all this in mind, it is our pleasure to invite you to learn more from the following pages about the activities in 2015, activities which have earned this centre a leading position in biomedical research to confront leukaemia.

Evarist Feliu  
President of the Delegate Committee  
Josep Carreras Leukaemia Research Institute (IJC)

# Who we are

## Three campuses united to win the battle against leukaemia and other malignant blood diseases

The Josep Carreras Leukaemia Research Institute (IJC), a Generalitat de Catalunya Research Centre (CERCA), was established with the aim of promoting biomedical research into, and the development of, personalised medicine in the field of malignant blood diseases, especially leukaemia. It is a centre without precedent which, with the work and dedication of researchers from around the world, uses the most innovative technologies to try to vanquish leukaemia and other malignant blood diseases.



The IJC has three independent and coordinated scientific campuses: the Hospital Clínic-UB Campus, located at the research facilities of Barcelona's Hospital Clínic, and those of the University of Barcelona (UB) Faculty of Medicine, coordinated by Dr. Álvaro Urbano Ispizua, under the research direction of Dr. Pablo Menéndez; the Catalan Institute of Oncology/Germans Trias i Pujol Campus in Badalona, located near the Germans Trias i Pujol University Hospital and its research foundation and the Autonomous University of Barcelona (UAB) Germans Trias i Pujol Teaching Unit. The ICO-Germans Trias i Pujol Campus is coordinated by Dr. Evarist Feliu and the Research Director is Dr. Francesc Solé. The third campus is the Sant Pau Campus and its research foundation, located within the health care facilities of the Hospital de la Santa Creu i Sant Pau and the UAB's Sant Pau teaching unit, coordinated by Dr. Jordi Sierra. The IJC's Hospital Clínic-UB Campus reaffirms the UB Faculty of Medicine and the Hospital Clínic's scientific commitment to excellence in the field of hematology, which commenced with the work of Prof. Farreras Valentí and which has been able to continue thanks to the extraordinary work carried out by Prof. Ciril Rozman and those who studied under him.





# What we research

The opportunities offered by research into leukaemia and other malignant blood diseases are evident. The strategies for responding to these opportunities have to employ the methodologies and technologies that correspond to the challenges presented by the quest to find a cure for these diseases. Consequently, the lines of research that the Josep Carreras Leukaemia Research Institute has established are as follows:

- 01 Acute leukaemias
- Chronic lymphoproliferative syndromes 02
- 03 Chronic myeloproliferative neoplasms
- Monoclonal gammopathies 04
- 05 Myelodysplastic syndromes
- Malignant blood diseases and coagulation 06
- 07 Associated complications and therapeutic procedures
- Transplantation of hematopoietic progenitors and cell therapy 08
- 09 Epidemiological research
- Clinical research 10



# Mission

The Josep Carreras Leukaemia Research Institute's mission is to carry out research into the basic, epidemiological, preventive, clinical and transferable aspects of leukaemia and other malignant blood diseases in order to find a cure for them.

# Vision


The Josep Carreras Leukaemia Research Institute's vision is to be a world-renowned, multi-campus research centre of excellence that contributes towards improved outcomes and a cure for leukaemia and other malignant blood diseases through innovation, sustainability, social responsibility, talent and professional expertise.

# Values

- Altruism and example-setting.
- Patient-orientated, proximity.
- Staff commitment and correlation.
- Mutual respect.
- Corporate alignment.
- Participative and shared leadership.
- Continuing cooperation agreements and the forging of alliances.
- The integration of research and health care.
- Continuous improvement and perseverance.
- Conceptual, methodological and technological innovation.
- Sustainable management.
- Procedural efficacy.
- Efficiency in the optimisation of resources.
- Transparency and public dissemination.
- Continuous evaluation and accountability.



# Schematic model





# Our team





# Governing bodies

The highest governing body is the Board of Trustees, on which are represented: the Josep Carreras Foundation, the Catalan Government Ministry of Business and Knowledge, the Catalan Government Ministry of Health, the Autonomous University of Barcelona (UAB), the University of Barcelona (UB), Badalona Town Council, the Directorate General for Health Research and Planning, the Catalan Institute of Oncology, the Northern Metropolitan Territorial Area Administration, the Catalan Foundation for Research and Innovation, the Hospital Clínic/August Pi i Sunyer Institute for Biomedical Research (Idibaps), the UB Hospital Coordination Committee and the Research Centres of Catalonia Institution Foundation (ICERCA).

## Board of Trustees

### President

#### **Mr. Josep Carreras Coll**

President of the Josep Carreras Foundation and the Josep Carreras Leukaemia Research Institute

#### **First Vice-president**

Catalan Government Minister of Business and Knowledge

#### **Second Vice-president**

Catalan Government Minister of Health

#### **Members**

Rector Autonomous University of Barcelona (UAB)  
Rector University of Barcelona (UB)

Mayor of Badalona

---

Director General for Research, Catalan  
Government Ministry of Business and Knowledge

Director General for Health Research and Planning

Deputy Director General for Health Research and  
Innovation

Director General Catalan Institute of Oncology

Administrator Northern Metropolitan Territorial Area

Secretary for Universities and Research, Catalan  
Government Ministry of Business and Knowledge

Director Catalan Foundation for Research and  
Innovation

Research Director Hospital Clínic - IDIBAPS

Treasurer of the Josep Carreras Leukaemia  
Foundation

Vice-president of the Josep Carreras Leukaemia  
Foundation

Trustee of the Josep Carreras Leukaemia  
Foundation

Administrator of the Josep Carreras Leukaemia  
Foundation

Vice-rector for Research and Transferability,  
Autonomous University of Barcelona (UAB)

University of Barcelona Hospital Coordination  
Committee

#### **Secretary**

Director of the Research Centres of Catalonia  
Institution Foundation (ICERCA)





### Delegate committee

---

#### President

**Prof. Evarist Feliu,**  
Coordinator of the ICO-Germans Trias i Pujol  
Campus

#### Members

PRICS coordinator, Catalan Government Ministry of  
Health

Director General, Catalan Government Ministry of  
Health, Directorate General Health Resources  
Planning Regulation

Directorate General for Research, Catalan  
Government Ministry of Business and Knowledge

Director iCerca, CERCA Institution, Research  
Centres of Catalonia

Administrator, Josep Carreras International  
Foundation

University of Barcelona Commissioner for Hospital  
Coordination

Vice-rector for Strategic Projects and Planning,  
Autonomous University of Barcelona

### CoExternal Scientific Committee

---

#### President

Prof. Lucio Luzzatto, Instituto Toscano Tumori  
Firenze

#### Members

Prof. Robert Sackstein, Dana-Farber/Harvard  
Cancer Center Boston

Prof. Francesco Lococo, Università degli Studi di  
Roma "Tor Vergata"

Prof. Alberto Orfao, CIC Centro de Investigación del  
Cáncer Salamanca.

Prof. Brigitte Schlegelberger, University of  
Hannover

#### Internal Scientific Committee

---

#### UB-Clínic Campus

Álvaro Urbano Ispizúa (Internal Scientific  
Committee Coordinator)

Pablo Menéndez (Campus Research Director)

Jordi Esteve Reyner

Armando López Guillermo

Joan Bladé Creixentí

Francisco Cervantes Requena

#### ICO-GTiP Campus

Evarist Feliu Frasnado (President of the Delegate  
Committee)

Francesc Solé (Campus Research Director)

Josep M<sup>a</sup> Ribera Santasusana

Lurdes Zamora Plana

José Tomás Navarro Ferrando

Juan Manuel Sancho Cía

#### Sant Pau Campus

Jordi Sierra

Josep Nomdedeu

Joan Carles Souto


Ramon Mangues

Carol Moreno





# Organisational chart



## Scientific directors



Campus ICO-GTP  
Francesc Solé



Campus Clínic-UB  
Pablo Menéndez



Campus Sant Pau  
Jordi Sierra

# Human resources

## IJC Germans Trias

---

### Linked with IJC

Aranda Cebrian, Jessica  
Barque Falguera, Anna  
Batista, Lopes  
Buschbeck, Marcus  
Cid Roldos, Emili  
Corujo Garcia, David  
Couso de la Torre, Jorge  
de Haro Camps, Núria  
Diesch, Jeannine  
Douet Julien, Thierry  
Estrada Barreras, Natalia  
Fita Torro, Josep  
Fuster Tormo, Francisco  
Garcia Calduch, Olga  
Garcia Rico, Laura  
Genesca Ferrer, Eulalia  
Gomes Monteiro, Maria Joao  
Gomez Marzo, Paula  
Guberovic, Iva  
Hurtado, Sarah  
Ibarra Fernandez, Gladys  
Llobet Reixach, Laura  
Maher, Michael  
Malinverni, Roberto  
Mallo Fajula, Maria del Mar  
Muncunill Farreny, Josep  
Palomo Sanchis, Laura  
Pasquali, Lorenzo  
Petritz Gonzalez, Jorge Mario  
Ribera Salas, Jordi  
Ruiz Cortes, Rocio  
Sanchez Fernandez, M Carmen  
Solanes Hernandez, Neus  
Sole Ristol, Francesc  
Valero Lazaro, Vanesa  
Vavouri, Soultana  
Vidal Santorum, Adria  
Yamamoto, Fumiichiro  
Yamamoto, Miyako

## IJC Clínic

---

### Linked with IJC

Agraz Doblas, Antonio Manuel  
Banus Mulet, Antonia  
Bueno Uroz, Clara  
Castaño Cardoso, Julio  
Cobo Sanchez, Isabel  
Díaz de la Guar Quiles, Rafael  
Dominguez Mohedano, Sonia  
Etxabe Alberdi, Amaia  
Fernandez Martin, Adrian  
Gutierrez Valle, Victoria  
Krishnevskaya, Elena  
Libero Baroni, Matteo  
Llaudet Planas, Esther  
Lopez Millan, Belen  
Mañu Pereira, Maria del Mar  
Masso Chacon, Anna  
Menendez Bujan, Pablo  
Mir Fuertes, Enrique  
Molina Campoy, Oscar  
Muñoz Risueño, Ruth  
Palomo de Udaeta, Marta  
Prieto Fernandez, Cristina  
Rizzutto, Valeria  
Roca Ho, Heleia  
Rodriguez Cortez, Virginia  
Suñe Rodriguez, Guillermo  
Torres Ruiz, Raul

## IJC Sant Pau

---

### Linked with IJC

Aljarilla Medina, Alba  
Esquirol Sanfeliu, Albert  
Millon Caño, Juan Antonio  
Virgin Alamo Vargas, Patricia



## IJC Germans Trias



## IJC Clínic



## IJC Sant Pau



## IJC Germans Trias

### Linked with hospital

Batlle, Montse. Post doc  
Cabezón, Marta. Post doc  
Cisneros, Adela. Pre doc  
Feliu, Evarist. Director  
Ferra, Christelle. LR  
Granada, Isabel. Post doc  
Grau, Javier. Post doc  
Junca, Jordi. Post doc  
Marce, Silvia. Post doc  
Milla, Fuensanta. Post doc  
Navarro, Tomàs. LR  
Oriol, Albert. LR  
Ribera, Josep Maria. LR  
Rodríguez, Inés. Pre doc  
Ruiz, Neus. Pre doc  
Sancho, Juanma. LR  
Vives, Susana. Pre doc  
Xandri, Marisol. Pre doc  
Xicoy, Blanca. LR  
Zamora, Lurdes. LR

## IJC Clínic

### Linked with hospital


Blade, Joan. LR  
Esteve, Jordi. LR  
Larrea, Carlos. Post doc  
Urbano, Alvaro. Director

## IJC Sant Pau

### Linked with hospital

Barata, Ana. Post doc  
Briones, Javier. LR  
Mangues, Ramon. LR  
Moreno, Carol. LR  
Nomdedeu, Josep LR  
Sierra, Jordi. Director


	IJC ICO Germans Trias UAB	IJC Clínic UB	IJC Sant Pau UAB	IJC Shared
Lead researchers	7	2		
Pre-doctoral researchers	9	7		
Post-doctoral researchers	6	7		
Support staff	11	6	3	
Management and administration staff	1			24
<b>Staff professionally linked with the IJC</b>	<b>34</b>	<b>22</b>	<b>3</b>	<b>24</b>
<b>Staff professionally linked with the Hospital</b>	<b>30</b>	<b>15</b>	<b>19</b>	








At the three hospitals where the IJC has a presence there has always been a great willingness to participate in clinical research. And there are clinics with a very considerable background in basic sciences. Integration, in this respect, must therefore not be just a question of maintaining present levels, but of increasing them in order to enhance the added value it represents in both the health sciences and in clinical practice.





# Financial data



# Income statement

In 2015 there was an increase of more than 180% in income from the capture of public funds and the provision of services.

With regard to expenses, 50% of the IJC's outlay corresponds to staffing, with an increase of almost 190% corresponding to the integration of new research teams (SUMA project). At this early stage the evolution of income, expenses and investments gives a negative result of €441,474.43.

<b>Income from activities</b>	<b>€3.378.582.43</b>
Services rendered	€530.190.71
Official subsidies for activities	€1.854.669.51
Other subsidies. donations...	€993.722.21
<b>Self-constructed assets</b>	<b>€33.567.19</b>
<b>Supplies</b>	<b>- €1.014.359.01</b>
<b>Other income from activity</b>	<b>€10.402.02</b>
<b>Staff costs</b>	<b>- €1.930.020.11</b>
Wages and salaries	- €1.495.891.70
Social security expenses	- €434.128.41
<b>Other expenses</b>	<b>- €508.978.06</b>
External services	- €469.076.88
Taxes	- €359.20
Losses. depreciation...	- €33.567.19
Other current period losses	- €5.974.79
<b>Fixed asset depreciation</b>	<b>- €441.474.43</b>
<b>IJC Subsidy</b>	<b>€47.270.14</b>
<b>Other income</b>	<b>€9.45</b>
<b>OPERATING INCOME</b>	<b>- €425.000.38</b>
<b>Financial income</b>	<b>€1.264.85</b>
<b>Financial expenses</b>	<b>- €15.155.43</b>
<b>Subsidy return expenses</b>	
<b>Exchange rate differences</b>	<b>- €2.583.47</b>
<b>Financial result</b>	<b>- €16.474.05</b>
<b>Surplus / deficit before tax</b>	<b>- €441.474.43</b>
Tax on profit	-
<b>SURPLUS / DEFICIT OF THE FINANCIAL YEAR</b>	<b>- €441.474.43</b>




# Balance sheet

<b>ASSETS</b>	
<b>Non-current assets</b>	<b>€10,682,445.23</b>
Intangible fixed assets	€ 2,133,999.05
Tangible fixed assets	€8,515,466.90
Long-term investments in group and associated entities	€2,000.00
Long-term financial investments	€30,979.28
<b>Current assets</b>	<b>€5,764,934.53</b>
Stock	€3,200.00
Users, sponsors and other debtors from activities	€4,824,792.62
Other credits with the public administration	
Short-term financial investments	€1,842.87
Short-term accruals	€40,413.37
Cash and others	€894,685.67
<b>TOTAL ASSETS</b>	<b>€16,447,379.76</b>

<b>LIABILITIES</b>	
<b>Net assets</b>	<b>€8,235,607.91</b>
<b>Equity</b>	<b>€6,988,786.30</b>
Start-up funds	€7,907,972.48
Special funds	
Profit or loss from previous years	- €477,711.75
Year profit or loss	- €441,474.43
Subsidies, donations and legacies	€1,246,821.61
<b>Non-current liabilities</b>	<b>€3,232,070.21</b>
Long-term debt	€3,232,070.21
<b>Current liabilities</b>	<b>€4,979,701.64</b>
Short-term provisions	€41,567.19
Short-term debt	€2,917,787.95
Creditors for activities and others	€1,318,832.01
Short-term debts with group and associated entities	
Current tax liabilities and other debts with the public administration	
Short-term accruals	€701,514.49
<b>TOTAL (LIABILITIES + NA)</b>	<b>€16,447,379.76</b>



# Evolution of income








# Scientific activity



# Research groups



## IJC Germans Trias

## IJC Clínic

Active projects

Active projects

18

18

LRs

LRs


7

2

# Research projects


IP	Projects 2015	Amount
PABLO MENENDEZ	ERC	€2.000.000,00
ALVARO MUÑOZ	FPI MINECO	€88.400,00
F SOLE	FEDER	€336.698,60
F SOLE	PEJ MINECO	€35.800,00
SOULTANA VAVOURI	RyC MINECO	€26.623,00
DAVID CORUJO	FPU MECD	€64.534,00
MARCUS BUSCHBECK	RyC MINECO	€24.403,00
SOULTANA VAVOURI	BFU-30246	€39.980,00
M <sup>a</sup> CARMEN SANCHEZ	SAF-40106	€54.175,00
		<b>€2.670.613,60</b>





# Capturing competitive grants

	ICO Germans UAB	Clínic UB
Active projects (national)	16	16
Projects awarded (national)	6	1
Projects tendered (national)	37	17
Active projects (international)	1	2
Projects awarded (international)	1	1
Projects tendered (international)	8	6
Projects awarded (public)	17	2
Projects awarded (private)	16	8
Active research networks	1	
Research networks awarded		
<hr/>		
Competitive funding granted (€)	€603.359,00	€2.088.400,00
Non-competitive funding granted (€)	€675.305,00	€255.227,00
Sum total competitive and non-competitive overheads granted	€221.967,00	€455.964,00



# Technology platforms

This year new equipment has arrived, such as the Fluidigm and a MFB Bioscience stereology system for the morphological study of lymphocyte populations.

## Cytogenetics platform



The Josep Carreras Leukaemia Research Institute cytogenetics platform is directed by Dr. Francesc Solé. The platform includes the Catalan Institute of Oncology's (ICO) Cytogenetics Laboratory and the 32K Bacterial Artificial Chromosome (BAK) library.

---

## Affymetrix Microarrays Platform



The Affymetrix® Microarrays Platform (AMP) is a service focused on microarray DNA and RNA solutions provided by Affymetrix. The main aim is to find solutions, based on basic research, applied research and diagnosis, that lead towards personalised medicine.

---

## Blood cancer samples



The administration of the collection, processing and storage of blood cancer samples. These samples are stored in a collection called 'Collection of samples from patients with hematologic neoplasms'.


---

## Fluidigm Platform



The Fluidigm platform is used to create integrated fluid circuits (IFCs) which are single-use biochips which automate PCR reactions using the volumes of nanolitres from two samples and reagents to produce consistent results.






# Clinical trials

Clinical trials are a fundamental part of our research. In this regard, the IJC evaluates treatments, the efficacy of drugs, and the suitability of equipment.

It enables new treatments to be tested to prevent, relieve or cure diseases.



# Transferability and innovation

The IJC vouches for the transferability of knowledge, and the value of and search for market opportunities, in the broadest terms. As well as being in its own interests, it contributes to society and our country's progress.

At the present time the IJC has the following patent pending:

**Methods for treating diagnosing and prognosing a haematological malignancy.**

Inventor: Ruth Muñoz Risueño

WO 2015/197839

PCT/EP2015/064571




# Scientific production



# Publications

## Indexed articles



## Publications 2016

Total FI articles

**80**

Accumulated impact factor

**509.926**


Total citations

**1,221**

Citation index

**39.976**


## Global impact factor







# Teaching activities



# Teaching

The IJC provides a high-quality teaching programme for students, scientists, technicians and others with an interest in achieving a solid and up-to-date grounding in the field of leukaemia and malignant blood diseases.

The IJC organises a Doctorate in Hematology, a Master's degree in malignant blood diseases and it participates in the teaching for degrees in medicine and biomedicine.

In 2015 the following theses were presented at the IJC:

**Molecular characterisation of tumour cells circulating in the peripheral blood of patients with breast cancer**

Doctoral student: Rosa Nadal Ríos (UAB)

Directors: Francesc Solé, Dr. Rafael Rosell and Dr. M<sup>a</sup> José Serrano  
Badalona, 23 January 2015

**Combination of cytogenetic techniques in chronic lymphocytic leukaemia**

Doctoral student: Anna Puiggros (UAB)

Directors: Francesc Solé, Blanca Espinet  
Barcelona, 10 July 2015

**Bone density variations in hematopoietic progenitor transplants**

Doctoral student: S Holgado Perezl (UAB)

Directors: JM Ribera and A Olive  
Badalona, 3 November 2015





# Training

The IJC organises complementary training activities at all levels, from scientific conferences, monthly seminars and technology sessions, to specialised courses.

Training courses


4

Scientific conference

1

Scientific seminars

12



# Internal sessions

**MDS GRUP**  
**FRANCESC SOLE**  
Mar Mallo  
Vera Ademà

**MPN GROUP**  
**LURDES ZAMORA, BLANCA XICOY**  
Laura Palomo


**GLICOLSILATION GROUP**  
**FUMI YAMAMOTO**  
Emili Cid

**ALL GROUP**  
**JM RIBERA**  
Eulalia Genescà  
Jordi Ribera  
Guillem Berbis

**MYELOMA GROUP**  
**ALBERT ORIOL**  
Paula Gomez

**IRON GROUP**  
**MAYKA SANCHEZ**  
Jorge Couso

**CHROMATIN GROUP**  
**MARCUS BUSCHBECK**  
Roberto Malinvemi  
Julien Douet  
Sara Alvarez



# Courses

**Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.**

Directors: Francesc Solé. Col.laboradors: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.

Badalona, 12 and 13 May 2015

**Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.**

Directors: Francesc Solé. Col.laboradors: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.

Badalona, 26 and 27 May 2015

**Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.**

Directors: Francesc Solé. Col.laboradors: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.

Badalona, 16 and 17 June 2015

**CUBIMOL. Paper: Cytogenetic and genetic changes in myelodysplastic syndromes.**

Speaker: Francesc Sole

Madrid 23-25 September 2015





# Cooperation



# Agreements

The IJC makes a great effort to establish continuing cooperation agreements, and it focuses on broadening its strategic alliances and agreements with the pharmaceutical industry, as well as other private organisations.

At the present time the following institutions are connected with the IJC:





# Communication




Josep Carreras  
LEUKAEMIA  
Research Institute



The IJC knows that it is of prime importance to tell people about the work we do if we are to strengthen our bonds with society and its citizens. The desire to integrate social corporate responsibility into our management model is closely linked to the organisational values of the Josep Carreras Foundation.

To this end, the IJC has actively participated in scientific dissemination and in the creation of scientific vocations.

Science week, Badalona town council




Dibuix Roser Bosch





# Upcoming challenges



# Upcoming challenges

## Construction of the new building in Badalona



In the summer of 2017 the IJC will take a big step forward in the field of research into leukaemia with the inauguration of the new building in Badalona.

The new building has 7,000m<sup>2</sup> of floor space, and it is the first European research centre to be exclusively focused on research into leukaemia and other malignant blood diseases.

Furthermore, it has been accredited as a sustainable building on account of its reduced environmental impact, savings in energy consumption, reduction in maintenance costs and the increased satisfaction and wellbeing of the people who use it.

## SUMA agreement



The Government of the Generalitat de Catalunya has approved the project for the integration of the Institute for Predictive and Personalised Cancer Medicine (IMPPC) with the IGTP and the IJC, and there is a proposal for an agreement that the administrator of the IGTP should also be the administrator of the IJC.

In this regard, work is taking place, together with the scientific management of the Germans Trias i Pujol Institute, with a view to sharing platforms and projects, and drafting a collaboration agreement which, once signed, can be applied to the other campuses.





# Annex



## Scientific production 2015

1. **BUENO C**, SARDINA JL, DI STEFANO B, ROMERO-MOYA D, CHILLÓN MC, BALANZATEGUI A, MUÑOZ-LÓPEZ A, CASTAÑO J, HERREROS A, FRAGA MF, FERNÁNDEZ A, CAMPOS D, **GRANADA I**, QUINTANA-BUSTAMANTE O, SEGOVIA JC, NISHIMURA K, OHTAKA M, GRAF T, NAKANISHI M & **MENENDEZ P**. Reprogramming primary human B-cells into induced pluripotent stem cells. *Leukemia* 2015 (in press). **IF: 9.379. Q1.**
2. SORIA-VALLES C, OSORIO FG, GUTIÉRREZ-FERNÁNDEZ A, DE LOS ANGELES A, **BUENO C, P. MENÉNDEZ**, DALEY GQ, FREIJE JMP & LÓPEZ-OTÍN C. NF- $\kappa$ B activation impairs somatic cell reprogramming in ageing. *Nature Cell Biol* 2015 (in press). **IF: 20.3. Q1.**
3. AYLLON V, **BUENO C**, RAMOS-MEJÍA V, REAL P, ROMERO T, NAVARRO-MONTERO O, GARCÍA-LEÓN MJ, TORIBIO ML, BIGAS A, **MENENDEZ P\***. The Notch ligand DLL4 marks human hematoendothelial progenitors and regulates their hematopoietic vs endothelium fate. *Leukemia* 2015. (in press). **IF: 9.379. Q1**
4. PINO-BARRIO MJ, GARCÍA-GARCÍA E, **MENÉNDEZ P**, MARTÍNEZ-SERRANO A. V-Myc immortalization of human neural stem cells induces self-renewal without activating a complete reprogrammed-like status. *PLoS ONE* 2015; 10: e0118499. **IF: 3,534. Q1.**
5. ALFRANCA A, MARTÍNEZ-CRUZADO L, TORNÍN J, ABARRATEGI A, AMARAL T, DE ALAVA E, **MENÉNDEZ P**, GARCÍA-CASTRO J, RODRÍGUEZ R. Bone microenvironment signals in osteosarcoma development. *Cell Mol Life Sci*. 2015 (in press). **IF: 5.9. Q1**
6. QI S, FANG Z, WANG D, **MENENDEZ P**, YAO K, JI J. Induced Pluripotency by Defined Factors: Prey of Oxidative Stress. *Stem Cells* 2015; 33:1371-1376. **IF: 7.133. Q1**
7. TOSCANO M, NAVARRO-MONTERO O, AYLLON V, RAMOS-MEJIA V, **BUENO C**, ROMERO T, COBO M, MARTIN F, **MENENDEZ P\***, P. REAL\*. SCL/TAL1-mediated transcriptional network enhances megakaryocytic differentiation of human embryonic stem cells. *Mol Ther* 2015; 23:158-170. **IF: 6.425**
8. MARTÍN-ANTONIO B, NAJJAR A, ROBINSON S, CHEW C, LI S, YVON E, THOMAS M, MCNIECE I, ORLOWSKI R, MUNOZ-PINEDO C, **BUENO C, MENENDEZ P**, FERNÁNDEZ DE LARREA C, **URBANO-ISPIZUA A**, SHPALL E, SHAH N. Transmissible Cytotoxicity Of Multiple Myeloma Cells By Cord Blood-Derived NK Cells Is Mediated By Vesicle Trafficking. *Cell Death Diff* 2015; 22:96-107. **IF: 8.385**
9. FERNÁNDEZ AF, BAYÓN GF, URDINGUIO RG, TORAÑO EG, GARCÍA M, CARELLA A, PETRUS-REURER S, FERRERO C, MARTINEZ-CAMBLOR P, CUBILLO I, GARCÍA-CASTRO J, DELGADO-CALLE J, RIANCHO JA, **BUENO C, MENÉNDEZ P**, MENTINK A, MARESCHI K, CLAIRE F, FAGNANI C, MEDDA E, TOCCACELI V, BRESCIANINI S, MORAN S, ESTELLER M, STOLZING A, DE BOER J, NISTICÒ L, STAZI MA, FRAGA MF. H3K4me1 marks DNA regions hypomethylated during aging in stem and differentiated cells. *Genome Res* 2015; 25:27-40. **IF: 14.5**
10. NADAL R, SALIDO M, NONELL L, RODRÍGUEZ-RIVERA M, PUIGDECANET E, MACIÀ M, COROMINAS JM, SERRANO MJ, LORENTE JA, **SOLÉ F**. Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status. *Tumor Biology* 2015; 36(2):711-718. PMID: 2528675. **IF 2.840. Q2**





11. MOHTY M, MALARD F, ABECASSIS M, AERTS E, ALASKAR AS, ALJURF M, ARAT M, BADER P, BARON F, BAZARBACHI A, BLAISE D, CICERI F, CORBACIOGLU S, DALLE JH, DUARTE RF, FUKUDA T, HUYNH A, MASSZI T, MICHALLET M, NAGLER A, NICHONGHAILE M, PAGLUICA T, PETERS C, PETERSEN FB, RICHARDSON PG, RUUTU T, SAVANI BN, WALLHULT E, YAKOUB-AGHA I, **CARRERAS E**. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant* 2015 Jun;50(6):781-9. doi: 10.1038/bmt.2015.52. Epub 2015 Mar 23. **IF. 3,466 Q2**
  
12. **CARRERAS E**. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. *Br J Haematol* 2015 Feb;168(4):481-91. doi: 10.1111/bjh.13215. Epub 2014 Nov 17. **IF: 4,959. Q1**
  
13. ARAI S, ARORA M, WANG T, SPELLMAN SR, HE W, COURIEL DR, **URBANO-ISPIZUA A**, CUTLER CS, BACIGALUPO AA, BATTIWALLA M, FLOWERS ME, JUCKETT MB, LEE SJ, LOREN AW, KLUMPP TR, PROCKUP SE, RINGDÉN OT, SAVANI BN, SOCIÉ G, SCHULTZ KR, SPITZER T, TESHIMA T, BREDESON CN, JACOBSON DA, HAYASHI RJ, DROBYSKI WR, FRANGOUL HA, AKPEK G, HO VT, LEWIS VA, GALE RP, KORETH J, CHAO NJ, ALJURF MD, COOPER BW, LAUGHLIN MJ, HSU JW, HEMATTI P, VERDONCK LF, SOLH MM, NORKIN M, REDDY V, MARTINO R, GADALLA S, GOLDBERG JD, MCCARTHY PL, PÉREZ-SIMÓN JA, KHERA N, LEWIS ID, ATSUTA Y, OLSSON RF, SABER W, WALLER EK, BLAISE D, PIDALA JA, MARTIN PJ, SATWANI P, BORNHÄUSER M, INAMOTO Y, WEISDORF DJ, HOROWITZ MM, PAVLETIC SZ; Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant* 2015 Feb; 21(2):266-74. doi: 10.1016/j.bbmt.2014.10.021. Epub 2014 Oct 30. **IF. 3,348. Q1**
  
14. QUEIRÓS A, VILLAMOR N, CLOT G, MARTINEZ-TRILLOS A, KULIS M, NAVARRO A, MURGA PENAS EM, JAYNE S, MAJID A, RICHTER J, BERGMANN A, KOLAROVA J, ROYO C, RUSSIÑOL N, CASTELLANO G, PINYOL M, BEA S, SALAVERRIA I, LÓPEZ-GUERRA M, COLOMER D, AYMERICH M, ROZMAN M, DELGADO J, GINÉ E, GONZÁLEZ M, PUENTE XS, SIEBERT R, DYER M, LÓPEZ-OTÍN C, **ROZMAN C**, CAMPO E, LOPEZ-GUILLERMO A, MARTÍN-SUBERO JI. A B-cell epigenetic signature defines three biological subgroups of chronic lymphocytic leukemia with clinical impact. *Leukemia* 2015 Mar; 29(3):598-605. doi: 10.1038/leu.2014.252. Epub 2014 Aug 25. **IF. 9,379. Q1**
  
15. FALANTES JF, TRUJILLO P, PIRUAT JI, CALDERÓN C, MÁRQUEZ-MALAVER FJ, MARTÍN-ANTONIO B, MILLÁN A, GÓMEZ M, GONZÁLEZ J, MARTINO ML, MONTERO I, PARODY R, ESPIGADO I, **URBANO-ISPIZUA A**, PÉREZ-SIMÓN JA. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 2015 Apr; 15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23. **IF. 1,929. Q3**
  
16. ARORA M, HEMMER MT, AHN KW, KLEIN JP, CUTLER CS, **URBANO-ISPIZUA A**, COURIEL DR, ALOUSI AM, GALE RP, INAMOTO Y, WEISDORF DJ, LI P, ANTIN JH, BOLWELL BJ, BOYIADZIS M, CAHN JY, CAIRO MS, ISOLA LM, JACOBSON DA, JAGASIA M, KLUMPP TR, PETERSDORF EW, SANTARONE S, SCHOUTEN HC, WINGARD JR, SPELLMAN SR, PAVLETIC SZ, LEE SJ, HOROWITZ MM, FLOWERS ME. Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. *Biol Blood Marrow Transplant* 2015 Apr; 21(4):640-5. doi: 10.1016/j.bbmt.2014.10.022. Epub 2014 Dec 18. **IF. 3,348. Q2**



17. ROSIÑOL L, JIMÉNEZ R, ROVIRA M, MARTÍNEZ C, FERNÁNDEZ-AVILÉS F, MARÍN P, SUÁREZ-LLEDÓ M, GUTIÉRREZ-GARCÍA G, FERNÁNDEZ DE LARREA C, CARRERAS E, **URBANO-ISPIZUA A**, BLADÉ J. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. *Bone Marrow Transplant* 2015 May; 50(5):658-62. doi: 10.1038/bmt.2014.320. Epub 2015 Jan 26. **IF. 3,466. Q2.**
18. INAMOTO Y, FLOWERS ME, WANG T, **URBANO-ISPIZUA A**, HEMMER MT, CUTLER CS, COURIEL DR, ALOUSI AM, ANTIN JH, GALE RP, GUPTA V, HAMILTON BK, KHARFAN-DABAJA MA, MARKS DI, RINGDÉN OT, SOCIÉ G, SOLH MM, AKPEK G, CAIRO MS, CHAO NJ, HAYASHI RJ, NISHIHORI T, RESHEF R, SAAD A, SHAH A, TESHIMA T, TALLMAN MS, WIRK B, SPELLMAN SR, ARORA M, MARTIN PJ. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. *Biol Blood Marrow Transplant* 2015 Oct;21(10):1776-82. doi: 10.1016/j.bbmt.2015.05.023. Epub 2015 May 30. PMID: 26033280. **IF. 3,348. Q2**
19. **URBANO-ISPIZUA A**, PAVLETIC SZ, FLOWERS ME, KLEIN JP, ZHANG MJ, CARRERAS J, MONTOTO S, PERALES MA, ALJURF MD, AKPEK G, BREDESON CN, COSTA LJ, DANDOY C, FREYTES CO, FUNG HC, GALE RP, GIBSON J, HAMADANI M, HAYASHI RJ, INAMOTO Y, INWARDS DJ, LAZARUS HM, MALONEY DG, MARTINO R, MUNKER R, NISHIHORI T, OLSSON RF, RIZZIERI DA, RESHEF R, SAAD A, SAVANI BN, SCHOUTEN HC, SMITH SM, SOCIÉ G, WIRK B, YU LC, SABER W. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. *Biol Blood Marrow Transplant* 2015 Oct;21(10):1746-53. doi: 10.1016/j.bbmt.2015.05.010. Epub 2015 May 15. PMID: 25981509. **IF. 3,348. Q2**
20. BRAULKE F, MÜLLER-THOMAS C, GÖTZE K, PLATZBECKER U, GERMING U, BRÜMMENDORF TH, NOLTE F, GIAGOUNIDIS A, LÜBBERT M, GREENBERG PL, SOLÉ F, MALLO M, BENNETT JM, SLOVAK ML, OHYASHIKI M, LE BEAU MM, TÜCHLER H, SHIRNESHAN K, PFEILSTÖCKER M, NÖSSLINGER T, HILDEBRANDT B, AUL C, STAUDER R, VALENT P, FONATSCH CH, TRÜMPER L, HAASE D, SCHANZ J. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. *Haematologica* 2015; 100(2):205-213. PMID: 25344522. **IF. 5,868. Q1.**
21. RAYA JM, MARTÍN-SANTOS T, LUÑO E, SANZO C, PEREZ-SIRVENT ML, SUCH E, NAVARRO JT, MILLÁ F, ALONSO E, DOMINGO A, ROZMAN M, DÍAZ-BEVA M, BATLLE A, GONZÁLEZ-DE-VILLAMBROSIA S, TUSET E, VALLESPÍ T, ORTEGA M, BERMEJO A, MARTÍN-RAMOS M, PERI V, **SOLÉ F**, FLORENSA L. On behalf of the Grupo Español de Citología Hematológica (GECH), Working Group into the Sociedad Española de Hematología y Hemoterapia (SEHH). Acute myeloid leukemia with inv (3)(q21q26.2) or t(3;3)(q21;q26.2): clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3. *Hematology* 2015 Feb 13. PMID: 25680074. **IF. 1,189. Q4.**
22. **ADEMA V**, LARRÁYOZ MJ, CALASANZ MJ, PALOMO L, PATIÑO A, AGUIRRE X, HERNANDEZ JM, LUMBRERAS E, BUÑO I, MARTINEZ-LAPERCHE C, GARCÍA O, ALVAREZ S, BLAZQUEZ B, CERVERA J, LUÑO E, VALIENTE A, VALLESPÍ MT, VICENTE A, MALLO M, ARENILLAS L, COLLADO R, PEREZ-TEYZA J, **SOLÉ F**. Prognostic implications of the involvement of TP53 and SETBP1 in myelodysplastic syndromes with i(17)(q10). *British Journal of Haematology* 2015. PMID: 25716545. **IF. 4,959. Q1**
23. DELLA PORTA M, TUECHLER H, MALCOVATI L, SCHANZ J, SANZ G, GARCIA-MANERO G, **SOLÉ F**, BENNETT JM, BOWEN D, FENAUX P, DREYFUS F, KANTARJIAN K, KUENDGEN A, LEVIS A, CERMAK J, FONATSCH CH, LE BEAU MM, SLOVAK ML, KRIEGER O, LUEBBERT M, MACIEJEWSKI J, MAGALHAES SSM, YASUSHI MIYAZAKI, PFEILSTÖCKER M, SEKERE M, SPERR WR, STAUDER R, TAURO S, VALENT P, VALLESPÍ T, VAN DE LOOSDRECHT AA, GERMING U, HAASE D, GREENBERG PL,



- CAZZOLA M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). *Leukemia* 2015. PMID. 25721895. FI. 9.379. Q1.
24. SÁNCHEZ-CASTRO J, BETÉS VM, GÓMEZ-ARBONÉS X, GARCÍA-CERECEDO T, LÓPEZ R, TALAVERA E, FERNÁNDEZ S, ADEMÀ V, MARUGAN I, LUÑO E, SANZO C, VALLESPÍ T, ARENILLAS L, MARCO BUADES J, BATLLE A, BUEÑO I, MARTÍN RAMOS ML, BLÁZQUEZ RIOS B, COLLADO NIETO R, VARGAS MT, GONZÁLEZ MARTÍNEZ T, SANZ GF, **SOLÉ F**. Fluorescence in situ hybridization (FISH) of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. *Leuk Lymphoma* 2015; 10:1-13. PMID: 25754580. **IF. 2.605. Q3**
25. MCGRAW K, ZHANG LM, ROLLISON DE, BASIORKA AA, FULP W, JEREZ A, BILLINGSLEY BL, LIN HY, KURTIN SE, YODER S, ZHANG Y, GUINTA K, MALLO M, SOLÉ F, CALASANZ MJ, CERVERA J, SUCH E, GONZÁLEZ T, SUNG S, NEVILL TJ, HAFERLACH T, MUFTI G, KARSAN A, MACIEJEWSKI JP, SOKOL L, EPLING-BURNETTE PK, WEI S, LIST AF. The Relationship of TP53 R72P Polymorphism to Disease Outcome and TP53 Mutation in del(5q) Myelodysplastic Syndromes. *Blood Cancer Journal* 2015. PMID: 25768405. **IF. 2.884. Q2.**
26. CASTILLO JJ, BOWER M, BRÜHLMANN J, NOVAK U, FURRER H, TANAKA PY, BESSON C, MONTOTO S, CWYNARSKI K, ABRAMSON JS, DALIA S, BIBAS M, CONNORS JM, FURMAN M, NGUYEN ML, COOLEY TP, BELTRAN BE, COLLINS JA, VOSE JM, **XICOY B, RIBERA JM**; for the HIV-Associated Hodgkin Lymphoma in the CART Era Study Group. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. *Cancer* 2015; 121(3):423-31. **IF. 4,901. Q1**
27. TOPP M, GÖKBUGET N, STEIN AS, ZUGMAIER G, O'BRIEN S, BARGOU RC, DOMBRET H, FIELDING AK, HEFFNER L, LARSON RA, NEUMANN S; FOÀ R, LITZOW M, **RIBERA JM**, RAMBALDI A, SCHILLER G, BRÜGGEMANN M, HORST HA, HOLLAND C, JIA C, MANIAR T, HUBER B, NAGORSEN D, FORMAN SJ, KANTARJIAN HM. Immunotherapy with CD19-targeting Bispecific T-Cell Engager Blinatumomab in Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukaemia"Immunotherapy with CD19-targeting Bispecific T-Cell Engager Blinatumomab in Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia". *Lancet Oncology* 2015; 16: 57-66. **IF. 24,725. Q1.**
28. **SORIGUE M, JUNCÀ J, SANCHO JM, MORGADES M, ESTEBAN D, NAVARRO JT, VIVES S, FELIU E, RIBERA JM**. Flow Cytometry for the Detection of Central Nervous System Disease in Acute Myeloblastic Leukemia. *Leuk Lymphoma* 2015 Feb 2:1-8. [Epub ahead of print] PubMed PMID: 25641427.
29. **VIVES A, ORIOL A, PIERNAS S, BRUNET S, CLAPÉS V, GUARDIA R, SUBIRÀ M, SIERRA J, RIBERA JM**; on behalf of the CETLAM Group. Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukemia aged 70 or older. *Eur J Hematol* 2015 Feb 17. doi: 10.1111/ejh.12538. [Epub ahead of print]
30. **BAPTISTA MJ, GARCIA O, MORGADES M, GONZALEZ-BARCA E, MIRALLES P, LOPEZ-GUILLERMO A, ABELLA E, MORENO M, SANCHO JM, FELIU E, RIBERA JM, NAVARRO JT**. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. *AIDS* 2015; 29(7):811-8. **IF. 6,577. Q1**



31. BARBA P, MARTINO R, MARTINEZ-CUADRON D, OLGA G, ESQUIROL A, GIL-CORTÉS C, GONZALEZ J, FERNANDEZ-AVILÉS F, VALCÁRCEL D, GUARDIA R, DUARTE RF, HERNANDEZ-RIVAS JM, ABELLA E, MONTESINOS P, **RIBERA JM**. Impact of transplant eligibility and the availability of an HLA-identical matched related donor on the outcome of older patients with acute lymphoblastic leukemia. *Leuk Lymphoma* 2015 Feb 17:1-16. [Epub ahead of print] PubMed PMID: 25686647.
32. BARTA SK, SAMUEL MS, XUE X, WANG D, LEE JY, MOUNIER N, **RIBERA JM**, SPINA M, TIRELLI U, WEISS R, GALICIER L, BOUE F, LITTLE RF, DUNLEAVY K, WILSON WH, WYEN C, REMICK SC, KAPLAN LD, RATNER L, NOY A, SPARANO JA. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. *Ann Oncol* 2015; 26(5):958-66. **IF. 6,578.**
33. KELLEHER N, **GARCIA O**, GALLARDO D, GONZALEZ J, HERNÁNDEZ JM, MONTESINOS P, SARRÀ J, GIL-CORTES C, BARBA P, GUÀRDIA R, BRUNET S, BERNAL T, MARTÍNEZ MP, ABELLA E, BERMÚDEZ A, SÁNCHEZ-DELGADO M, CLADERA A, GAYOSO J, CALBACHO M, **RIBERA JM**. Incidence, clinicobiological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. *Leuk Lymphoma* 2015 Apr 10:1-22 (in press)
34. TAPIA G, MD, **BAPTISTA MJ**, MUÑOZ-MARMOL AM, GAAFAR A, PUENTE-POMPOSOM, GARCIA O, MARGINET-FLINCH R, SAN C, **NAVARRO JT, SANCHO JM, RIBERA JM**, ARIZA A, MATE JL. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. *APMIS* 2015 Jul;123(7):596-603.
35. SANZ MA, MONTESINOS P, KIM HT, RUIZ-ARGÜELLES GJ, UNDURRAGA MS, URIARTE MR, MARTÍNEZ L, JACOMO RH, GUTIÉRREZ-AGUIRRE H, MELO RA, BITTENCOURT R, PASQUINI R, PAGNANO K, FAGUNDES EM, VELLENGA E, HOLOWIECKA A, GONZÁLEZ-HUERTA AJ, FERNÁNDEZ P, DE LA SERNA J, BRUNET S, DE LISA E, GONZÁLEZ-CAMPOS J, **RIBERA JM**, KRSNIK I, GANSER A, BERLINER N, RIBEIRO RC, LO-COCO F, LÖWENBERG B, REGO EM; IC-APL and PETHEMA and HOVON Groups. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. *Ann Hematol* 2015 May 15.[Epub ahead of print] PubMed PMID: 25975975.
36. **SANCHO JM, RIBERA JM**; en representación del Grupo de Trabajo sobre Diagnóstico, Prevención y Tratamiento de la Infiltración del SNC en pacientes con LBDCG. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors]. *Med Clin (Barc)* 2015 Mar 24. pii: S0025-7753(15)00075-5. doi: 10.1016/j.medcli.2014.12.025. [Epub ahead of print] Review. Spanish. PubMed PMID: 25817451.
37. BERNAL T, MARTÍNEZ-CAMBLOR P, SÁNCHEZ-GARCÍA J, DE PAZ R, LUÑO E, NOMDEDEU B, ARDANAZ MT, PEDRO C, AMIGO ML, XICOY B, DEL CAÑIZO C, TORMO M, BARGAY J, VALCÁRCEL D, BRUNET S, BENLLOCH L, SANZ G. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. *Leukemia* 2015 May 6. doi: 10.1038/leu.2015.115. [Epub ahead of print] PubMed PMID: 25943181.
38. **ZAMORA L, XICOY B, CABEZÓN M**, FERNANDEZ C, MARCÉ S, VELEZ P, **XANDRI M**, GALLARDO D, **MILLÁ F, FELIU E**, BOQUÉ C. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. *Leuk Lymphoma* 2015 Mar 11:1-2. [Epub ahead of print] PubMed PMID: 25686645.
39. NIEMEYER CM, LOH ML, CSEH A, COOPER T, DVORAK CC, CHAN R, **XICOY B**, GERMING U, KOJIMA S, MANABE A, DWORZAK M, DE MOERLOOSE B, STARÝ J, SMITH OP, MASETTI R, CATALA A, BERGSTRAESSER E, USSOWICZ M, FABRI O, BARUCHEL A, CAVÉ H, ZWAAN M, LOCATELLI F, HASLE H, VAN DEN HEUVEL-EIBRINK MM, FLOTHO C, YOSHIMI A. Criteria for evaluating response and



- outcome in clinical trials for children with juvenile myelomonocytic leukemia. *Haematologica* 2015; 100(1):17-22. **IF. 5,868. Q1**
40. **ZAMORA L**, GERMING U, CABEZÓN M, SCHULER E, ARNAN M, MARCÉ S, COLL R, POMARES H, BRINGS C, PALOMO L, SCHMENEAU J, GALLARDO D, **MILLÁ F, FELIU E, XICOY B**. Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia. *Ann Hematol* 2015; 94(5):869-71. **IF. 2,396. Q3**
  41. **SORIGUÉ M, XICOY B**, GRIFOLS JR, **RIBERA JM**. [Autoimmune hemolytic anèmia refractory to medical treatment after chlorine dioxide intake in a patient with idiopathic thrombocytopenic purpura]. *Med Clin (Barc)* 2015; 144(7):332-3. **IF. 1,252. Q3**
  42. **FERRÀ C**, SANZ J, DÍAZ-PÉREZ MA, **MORGADES M**, GAYOSO J, CABRERA JR, VILLAESCUSA T, SAMPOL MA, FERNÁNDEZ-AVILÉS F, SOLANO C, ORTÍN M, DUARTE R, CUESTA M, HERAS I, DE LA SERNA J, MORALEDA JM, BARRENETXEA C, GONZÁLEZ-VICENT M, SANZ G, **RIBERA JM**; Grupo Español de Trasplante Hematopoyético (Geth) Spanish Society of Hematology. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. *Leuk Lymphoma* 2015; 56: 656-62. **IF. 2,605. Q2**
  43. STEWART AK, RAJKUMAR SV, DIMOPOULOS MA, MASSZI T, ŠPIČKA I, **ORIOI A**, HÁJEK R, ROSIÑOL L, SIEGEL DS, MIHAYLOV GG, GORANOVA-MARINOVA V, RAJNICS P, SUVOROV A, IESVIZKY R, JAKUBOWIAK AJ, SAN-MIGUEL JF, LUDWIG H, WANG M, MAISNAR V, MINARIK J, BENSINGER WI, MATEOS MV, BEN-YEHUDA D, KUKRETI V, ZOJWALLA N, TONDA ME, YANG X, XING B, MOREAU P, PALUMBO A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2015; 372(2):142-52. **IF. 54,420. Q1**
  44. **ORIOI A**. Treatment of relapsed or refractory acute lymphoblastic leukemia in adult patients. *Acta Haematol* 2015;133(1):89-90. **IF. 0,994. Q4**
  45. **SANCHO JM, GARCÍA O**, MERCADAL S, POMARES H, FERNÁNDEZ-ALVAREZ R, GONZÁLEZ-BARCA E, TAPIA G, GONZÁLEZ-GARCÍA E, **MORENO M**, DOMINGO-DOMÈNECH E, SORIGUÉ M, **NAVARRO JT**, MOTLLÓ C, FERNÁNDEZ-DE-SEVILLA A, **FELIU E, RIBERA JM**. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. *Leukemia Research* 2015; 39: 853-858.
  46. BRITOS-FRANCO P, RODRÍGUEZ-HERNÁNDEZ I, **NAVARRO JT, GRANADA I, TAPIA G, JUNCÀ J, RIBERA JM, MILLÁ F**. Translocation (18;22)(q21;q11.2) in B-cell lymphoproliferative disorders: a report of six cases. *Leuk Lymphoma* 2015 Mar;56(3):789-92. doi: 10.3109/10428194.2014.928932. Epub 2014 Jul 17. No abstract available.
  47. **MARCÉ S**, CORTÉS M, **ZAMORA L, CABEZÓN M, GRAU J, MILLÁ F, FELIU E**. A Thirty-five Nucleotides *BCR-ABL1* Insertion Mutation of Controversial Significance Confers Resistance to Imatinib in a Patient with Chronic Myeloid Leukemia (CML). *Exp Mol Pathol* 2015 Apr 22; 99(1):16-18. [Epub ahead of print]. **IF. 2,881**
  48. **SORIGUÉ M, JUNCÀ J, MARCÉ S, CABEZÓN M, OLGA G, ZAMORA L**. The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies. *Leuk Lymphoma* 2015 May 8:1-10. [Epub ahead of print]. **IF. 2,605**





49. AGUADO JM, VÁZQUEZ L, FERNÁNDEZ-RUIZ M, VILLAESCUSA T, RUIZ-CAMPS I, BARBA P, SILVA JT, **BATLLE M**, SOLANO C, GALLARDO D, HERAS I, POLO M, VARELA R, VALLEJO C, OLAVE T, LÓPEZ-JIMÉNEZ J, ROVIRA M, PARODY R, CUENCA-ESTRELLA M; PCRAGA Study Group; Spanish Stem Cell Transplantation Group; Study Group of Medical Mycology of the Spanish Society of Clinical Microbiology and Infectious Diseases; Spanish Network for Research in Infectious Diseases. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based *Aspergillus* DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. *Clin Infect Dis* 2015; 60(3):405-14.
50. **RIBERA J, MORGADES M, ZAMORA L**, MONTESINOS P, GÓMEZ I, PRATCORONA M, SARRA J, GUARDIA R, NOMDEDEU J, TORMO M, MARTI J, HENÁNDEZ RIVAS JM, GONZÁLEZ S, BARBA P, ESCODA L, **GENESCÀ E, SOLÉ F, MILLÁ F, FELIU E, RIBERA JM**. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. *Cancer* (in press), 2015. **IF. 4,901**
51. PANTANO L, JODAR M, BAK M, BALLESCÀ JL, TOMMERUP N, OLIVA R, **VAVOURI T**. The small RNA content of human sperm reveals pseudogene-derived piRNAs complementary to protein-coding genes. *RNA* 2015 Jun;21(6):1085-95. doi: 10.1261/rna.046482.114. Epub 2015 Apr 22. PMID: 25904136.
52. RICKY JOSHI R\*, SHVARTSMAN M\*, MORÁN E, LOIS S, ARANDA J, BARQUÉ A, DE LA CRUZ X, BRUGUERA M, VAGACE JM, GERVASINI G, SANZ C, **SÁNCHEZ M**. Functional consequences of transferrin receptor-2 mutations causing Hereditary Hemochromatosis type 3. Accepted in *Molecular Genetics & Genomic Medicine* 2015.
53. DE FALCO L, SILVESTRI L, KANNENGIESSER C, MORÁN E, OUDIN C, RAUSA M, BRUNO M, ARANDA J, ARGILES B, YENICESU I, FALCON-RODRIGUEZ M, YILMAZ-KESKIN E, KOCÁK U, BEAUMONT C, CAMASCHELLA C, IOLASCON A, GRANDCHAMP B, **SANCHEZ M**. Functional and clinical impact of novel Tmprss6 mutations in Iron-Refractory Iron-Deficiency Anaemia patients and genotype-phenotype studies. Accepted in *Human Mutation*. **IF. 5.213, Q1**
54. TEIXEIRA E, BORLIDO-SANTOS J, BRISSOT P, BUTZECK B, COURTOIS F, EVANS RW, FERNAU J, NUNES JA, MULLETT M, PANEQUE M, PINEAU B, PORTO G, SORRILL R, **SANCHEZ M**, SWINKELS DW, TOSKA K, VARKONYI J; the EFAPH, the European Federation of Associations of Patients with Haemochromatosis. The importance of the general practitioner as an information source for patients with hereditary haemochromatosis. *Patient Educ Couns* 2014 May 5. pii: S0738-3991(14)00178-5. doi: 10.1016/j.pec.2014.04.017. [Epub ahead of print] **IF. 2,372 (2012 JCR), Q1D1**
55. CASTILLO N, GARCÍA-CADENAS I, GARCÍA O, BARBA P, HEREDIA CD, **MARTINO R**, AZQUETA C, FERRÀ C, CANALS C, ELORZA I, OLIVÉ T, BADELL I, **SIERRA J**, DUARTE R, VALCÁRCEL D, QUEROL S. Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. *Biol Blood Marrow Transplant*. 2014 Dec 27. pii: S1083-8791(14)01415-3. doi: 10.1016/j.bbmt.2014.12.015. [Epub ahead of print] PubMed PMID: 25545727. **IF. 3.348. Q2**
56. GARCÍA-CADENAS I, CASTILLO N, **MARTINO R**, BARBA P, ESQUIROL A, NOVELLI S, ORTI G, GARRIDO A, SAAVEDRA S, MORENO C, GRANELL M, BRIONES J, BRUNET S, NAVARRO F, RUIZ I, RABELLA N, VALCÁRCEL D, **SIERRA J**. Impact of Epstein Barr virus-related complications after high-risk



- allo-SCT in the era of pre-emptive rituximab. *Bone Marrow Transplant* 2015 Jan 12. doi: 10.1038/bmt.2014.298. [Epub ahead of print] PubMed PMID: 25581404. **IF. 3.466. Q2**
57. **MARTINO R**, BAUTISTA G, PARODY R, GARCÍA I, ESQUIROL A, ROVIRA M, CABRERA JR, REGIDOR C, FORES R, GARCÍA-MARCO JA, SERRANO D, BARBA P, HERAS I, MARQUEZ-MALAVER FJ, SÁNCHEZ-ORTEGA I, DUARTE R, SAAVEDRA S, VAZQUEZ L; The Infectious/Non-infectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH). Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34(+) cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). *Transpl Infect Dis* 2015 Feb 3. doi: 10.1111/tid.12361. [Epub ahead of print] PubMed PMID: 25652036. **IF. 2.250. Q2.**
58. MORENO MJ, BOSCH R, DIEGUEZ-GONZALEZ R, NOVELLI S, MOZOS A, GALLARDO A, PAVÓN MÁ, CÉSPEDES MV, GRAÑENA A, ALCOCEBA M, BLANCO O, GONZALEZ-DÍAZ M, **SIERRA J, MANGUES R**, CASANOVA I. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. *J Pathol* 2015 Feb;235(3):445-55. doi: 10.1002/path.4446. Epub 2014 Dec 11. PubMed PMID: 25231113. **IF. 7.330. Q1.**
59. PIÑANA JL, SANZ J, ESQUIROL A, MARTINO R, PICARDI A, BARBA P, PARODY R, GAYOSO J, MONTESINOS P, GUIDI S, TEROL MJ, MOSCARDÓ F, SOLANO C, ARCESE W, SANZ MA, **SIERRA J**, SANZ G; GETH GITMO groups. Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. *Eur J Haematol* 2015 Apr 2. doi: 10.1111/ejh.12557. [Epub ahead of print] PubMed PMID: 25845981. **IF. 2.414**
60. RUGGERI A, LABOPIN M, SANZ G, PIEMONTESE S, ARCESE W, BACIGALUPO A, BLAISE D, BOSI A, HUANG H, KARAKASIS D, KOC Y, MICHALLET M, PICARDI A, SANZ J, SANTARONE S, SENGELOV H, **SIERRA J**, VINCENT L, VOLT F, NAGLER A, GLUCKMAN E, CICERI F, ROCHA V, MOHTY M. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. *Leukemia* 2015 Apr 17. doi: 10.1038/leu.2015.98. [Epub ahead of print] PubMed PMID: 25882700. **IF. 9.379**
61. SAUMELL S, **SOLÉ F**, ARENILLAS L, MONTORO J, VALCÁRCEL D, PEDRO C, SANZO C, LUÑO E, GIMÉNEZ T, ARNAN M, POMARES H, DE PAZ R, ARRIZABALAGA B, JEREZ A, MARTÍNEZ AB, SÁNCHEZ-CASTRO J, RODRÍGUEZ JD, RAYA JM, RÍOS E, RODRÍGUEZ-RIVERA M, ESPINET B, FLORENSA L. Trisomy 8 in de novo myelodysplastic syndrome. Constitutional or not constitutional. *Plos One*. 12;10(6):e0129375. PMID: 26066831. **FI. 3.534.** TIPO PUBLICACIÓN: A.
62. BRAULKE F, MÜLLER-THOMAS C, GÖTZE K, PLATZBECKER U, GERMING U, HOFMANN WK, GIAGOUNIDIS A, LÜBBERT M, GREENBERG PL, BENNETT J, **SOLÉ F**, SLOVAK ML, OHYASHIKI K, LE BEAU MM, TÜCHLER H, PFEILSTÖCKER M, HILDEBRANDT B, AUL C, STAUDER R, VALENT P, FONATSCH CH, BACHER U, TRÜMPER L, HAASE DM, SCHANZ J. Results from a German diagnostic study in comparison with an international control group reveals that the frequency of del(12p) is commonly underestimated in Myelodysplastic Syndromes. *Genes Chromosomes and Cancer*. Genes 2015 Sep 10. doi: 10.1002/gcc.22292. PMID: 26355708. **FI. 4.041**
63. COSTA D, MUÑOZ C, CARRIÓ A, ARIAS A, GÓMEZ C, **SOLÉ F**, ESPINET B, AZACETA G, CALASANZ MJ, NOMDEDEU M, CALVO X, CAMPO E, NOMDEDEU B (2015). Refining breakpoints in three new apparently recurrent translocations identified in myelodysplastic syndromes. *Acta Haematologica* 135(2):94-100. PMID: 26509426. **FI. 1.116**



64. PALOMO L, XICOY B, GARCIA O, MALLO M, ADEMÀ V, CABEZÓN M, ARNAN M, POMARES H, LARRAYOZ MJ, CALASANZ MJ, MACIEJEWSKI JP, HUANG D, SHIH LY, OGAWA S, CERVERA J, SUCH E, COLL R, GRAU J, **SOLÉ F**, ZAMORA L (2015): Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. *Am J Hematol.* 2015 Oct 28. doi: 10.1002/ajh.24227. PMID: 26509444. **FI. 3.798**
65. NOMDEDEU M, CALVO X, PEREIRA A, CARRIÓ A, **SOLÉ F**, LUÑO E, CERVERA J, VALLESPÍ T, MUÑOZ C, GÓMEZ C, ARIAS A, SUCH E, SANZ G, GRAU J, INSUNZA A, CALSANZ MJ, ARDANAZ MT, HERNÁNDEZ JM, AZACETA G, ALVAREZ S, SÁNCHEZ J, MARTÍN ML, BARGAY J, GÓMEZ V, CERVERO CJ, ALLEGUE J, COLLADO R, CAMPO E, ESTEVE J, NOMDEDEU B, COSTA D, ON BEHALF OF THE SPANISH GROUP OF MYELOYDYSPLASTIC SYNDROMES. Prognostic impact of chromosomal translocations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemias. A study by the Spanish Group of Myelodysplastic Syndromes. *Genes Chromosomes and Cancer.* PMID: 26690722. **FI: 4.041**
66. MCGRAW K, CLUZEAU T\*, SALLMAN DA, BASIORKA AA, IRVINE BA, ZHANG L, BURNETTE E, ROLLISON DE, MALLO M, SOKOL L, **SOLÉ F**, MACIEJEWSKI J, LIST AF: *TP53* and *MDM2* single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. *Oncotarget.* PMID: 26416416. **FI. 6.627**
67. **RIBERA JM.** Leukaemic vasculitis from myelodysplastic syndrome in context. *Lancet.* 2015;386(9992):502.
68. SPINA M, NAGY Z, **RIBERA JM**, FEDERICO M, AURER I, JORDAN K, BORSARU G, PRISTUPA AS, BOSI A, GROSICKI S, GLUSHKO NL, RISTIC D, JAKUCS J, MONTESINOS P, MAYER J, REGO EM, BALDINI S, SCARTONI S, CAPRIATI A, MAGGI CA, SIMONELLI C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. *Ann Oncol.* 2015;26(10):2155-61.
69. JOSEP-MARIA RIBERA; ALBERT FERRER; JORDI RIBERA; EULÀLIA GENESCÀ. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. *OncoTargets and therapy.* 8, pp. 1567 - 1641. Dove Medical Press, 24/06/2015. ISSN 1178-6930.
70. BERNAT GEL, ANNA DIEZ-VILLANUEVA, EDUARD SERRA, **MARCUS BUSCHBECK**, MIGUEL A. PEINADO AND **ROBERTO MALINVERNI.** regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. *Bioinformatics* 2015 in press IF 4.981
71. RICKY JOSHI R, SHVARTSMAN M, MORAN E, LOIS S, ARANDA J, BARQUE A, DE LA CRUZ X, BRUGUERA M, VAGACE CM, GERVASINI G, SANZ C, SANCHEZ M. Functional consequences of transferrin receptor-2 mutations causing Hereditary Hemochromatosis type 3. *Genetics & Genomic Medicine* 2015 May;3(3):221-32. doi: 10.1002/mgg3.136. Epub 2015 Mar 6. IF. 3.585
72. VANESSA BARRAGAN, YOLANDA DIAZ, CRISTINA JUAN, **JORDI RIBERA, JOSE TOMAS NAVARRO, FUENSANTA MILLÁ.** Leucemia linfoblástica aguda (LLA B) en un adulto con doble cromosoma Philadelphia (Ph<sup>1</sup>) y expresión de las isoformas p190 y p210. *Revista: AETEL* 15/09/2015, llibre 50, foli 13 i n° 102
73. **XICOY B**, GERMING U, **JIMENEZ MJ, GARCIA O, GARCIA R**, SCHEMENAU J, PEDRO C, LUÑO E, BERNAL T, GONZÁLEZ BJ, STRUPP C, ARDANAZ M, KUENDGEN A, CEDENA MT, NEUKIRCHEN J, CALABUIG M, BRUNET S, MEDINA A, AMIGO ML, RAMOS F, CALLEJAS M, DíEZ-CAMPELO M, BAILÉN



- A, COLLADO R, VICENTE A, ARNAN M, VALCARCEL D, ARILLA MJ, **ZAMORA L**, BENLLOCH L, SANZ GF. Response to erythropoietic stimulating agents in patients with chronic myelomonocytic leukemia. *Eur J Haematol*. 2015 Sep 5. doi: 10.1111/ejh.12679. [Epub ahead of print]. IF: 2.066
74. **SORIGUE M, JUNCA J, GRANADA I**. CD200 in High-Grade Lymphoma, Chronic Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia-Phenotype Monoclonal B-Cell Lymphocytosis. *Am J Clin Pathol*. 2015 Oct;144(4):677-9. doi: 10.1309/AJCPO2KKFHOEXNZF. No abstract available. PMID: 26386092. Similar articles
75. **RUIZ-XIVILLÉ N, GRANADA I, CAMPOS D, CISNEROS A, GRAU J, XANDRI M, ARNAN M, LLOVERAS N, ESCODA L, FONT L, MILLÀ F, RIBERA JM**. Clinical usefulness of fluorescence in situ hybridization for detection of MLL rearrangements in acute myeloid leukemia. *Leuk Lymphoma*. 2015 Feb 20:1-3. [Epub ahead of print] No abstract available. PMID: 25549805. Similar articles. Select item 25116331
76. **RIBERA JM, FERRER A, RIBERA J, GENESCÀ E**. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. *Onco Targets Ther*. 2015 Jun 24;8:1567-74. doi: 10.2147/OTT.S70524. eCollection 2015. Review. IF: 2,5
77. **GUILLEM BERBIS<sup>1</sup>, JORDI RIBERA<sup>1</sup>, JOSEP MARIA RIBERA<sup>1,2</sup>, EULÀLIA GENESCÀ**. Implications of basic research in clinical practice: toward a personalized medicine in T-cell Acute Lymphoblastic Leukemia (T-ALL). *Biological Science (Molecular Biology, OMICS group)*. Review. IF: 1,85. Accepted on 26.10.2015
78. Sánchez-Ortega I, Querol S, Encuentra M, Ortega S, Serra A, Sanchez-Villegas JM, Grifols JR, Pujol-Balaguer MM, Pujol-Bosch M, Martí JM, Garcia-Cerecedo T, Barba P, Sancho JM, et al. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. *Bone Marrow Transplant*. 2015; 50:34-39. **IF: 3,570**
79. Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. *Br J Haematol*. 2015; 169:188-98. **IF: 4,971**
80. Panizo C, Rodríguez AJ, Gutiérrez G, Díaz FJ, González-Barca E, de Oña R, Grande C, Sancho JM, et al; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea GELTAMO Spanish Cooperative Group. Evaluation of Clinical and Biological Prognostic Factors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients After Previous Treatment With Rituximab and Chemotherapy: Results of the PRO-R-IPi Study. *Clin Lymphoma Myeloma Leuk*. 2015; 15(7):398-403. **IF: 2,020**
81. Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Gonzalez ME, Rubio-Castro A, Dominguez-Iglesias F, Solano J, Alonso-Nogues E, Fernandez-Alvarez C, Zanabili Y, Alonso JM, Payer AR, Vicente JM, Medina J, Sancho JM. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. *Leuk Lymphoma*. 2015; 56:3096-102. **IF: 2,891**
82. Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, Gonzalez ME, Payer AR, Alonso-Garcia A, Rodriguez-Villar D, Dominguez-Iglesias F, Sancho JM. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. *Leuk Lymphoma*. 2015 Jun 18:1-4. **IF: 2,891**



83. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarzer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orłowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol*. 2015 Dec 3. pii: S1470-2045(15)00464-7. doi: 10.1016/S1470-2045(15)00464-7. **IF: 24,690**
  
84. Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, De La Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Blade J, Perez-Simon JA, San Miguel JF. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. *Blood*. 2015 Dec 14. pii: blood-2015-10-662320. **IF: 10,452**
  
85. Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martinez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martin ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. *Leuk Res Rep*. 2015; 4(2):64-9. **IF: 2,351**
  
86. Mateos MV, Martínez-Lopez J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J. Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. *Blood*. 2015 Oct 23. pii: blood-2015-08-666537. **IF: 10,452**
  
87. Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. *Haematologica*. 2015; 100(10):1327-33. **IF: 5,814**
  
88. Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. *Haematologica*. 2015; 100(10):1294-300. **IF: 5,814**
  
89. San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. *Haematologica*. 2015; 100(10):1334-9. **IF: 5,814**
  
90. Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidriales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordon L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. *Blood*. 2015; 126(7):858-62. **IF: 10,452**





91. García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV; Spanish Myeloma Group (GEM/PETHEMA). Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. *Haematologica*. 2015; 100(9):1207-13. **IF: 5,814**
92. Ocio EM, Oriol A, Bladé J, Teruel AI, Martín J, de la Rubia J, Gutiérrez NC, Rodríguez Díaz-Pavón J, Martínez González S, Coronado C, Fernández-García EM, Siguero Gómez M, Fernández-Teruel C, San Miguel J. Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma. *Br J Haematol*. 2015 Jun 2. doi: 10.1111/bjh.13515. **IF: 4,971**
93. Cibeira MT, Oriol A, Lahuerta JJ, Mateos MV, de la Rubia J, Hernández MT, Granell M, Fernández de Larrea C, San Miguel JF, Bladé J; PETHEMA cooperative study group. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. *Br J Haematol*. 2015; 170(6):804-13. **IF: 4,971**
94. Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste MA, Sarrá J, Ocio E, Ramírez G, Martínez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea AI, Bladé J, Lahuerta JJ, San Miguel JF. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial. *Haematologica*. 2015; 100(8):1096-102. **IF: 5,814**
95. Oriol A, Giraldo P, Kotsianidis I, Couturier C, Olie R, Angermund R, Corso A. Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study. *Hematology*. 2015; 20(7):405-9. **IF: 1,253**
96. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015; 372(2):142-52. **IF: 55,873**
97. Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, Dimopoulos MA. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. *Br J Haematol*. 2015; 168(6):820-3. **IF: 4,971**
98. Paíno T, Paiva B, Sayagués JM, Mota I, Carvalheiro T, Corchete LA, Aires-Mejía I, Pérez JJ, Sanchez ML, Barcena P, Ocio EM, San-Segundo L, Sarasquete ME, García-Sanz R, Vidriales MB, Oriol A, Hernández MT, Echeveste MA, Paiva A, Bladé J, Lahuerta JJ, Orfao A, Mateos MV, Gutiérrez NC, San-Miguel JF. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. *Leukemia*. 2015; 29(5):1186-94. **IF: 10,431**
99. Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García-Noblejas A, Jimenez S, Sampol A, Yañez L, Garcia V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF. Outcome of second allogeneic HCT following relapse of myeloid malignancies post allogeneic HCT, a retrospective cohort on behalf of the GETH. *Biol Blood Marrow Transplant*. 2015 Nov 26. pii: S1083-8791(15)00739-9. doi: 10.1016/j.bbmt.2015.11.012. **IF: 3,404**



100. Santos N, Rodríguez-Romanos R, Nieto JB, Buño I, Vallejo C, Jiménez-Velasco A, Brunet S, Buces E, López-Jiménez J, González M, Ferrá C, Sampol A, de la Cámara R, Martínez C, Gallardo D. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation. *Bone Marrow Transplant*. 2015 Sep 14. doi: 10.1038/bmt.2015.207. **IF: 3,570**
101. Castillo N, García-Cadenas I, Barba P, Martino R, Azqueta C, Ferrà C, Canals C, Sierra J, Valcárcel D, Querol S. Post-Thaw Viable CD45(+) Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases. *Biol Blood Marrow Transplant*. 2015;12: 2167-72. **IF: 3,404**
102. Halter JP, Michael W, Schüpbach M, Mandel H, Casali C, Orchard K, Collin M, Valcarcel D, Rovelli A, Filosto M, Dotti MT, Marotta G, Pintos G, Barba P, Accarino A, Ferra C, Illa I, Beguin Y, Bakker JA, Boelens JJ, de Coo IF, Fay K, Sue CM, Nachbaur D, Zoller H, Sobreira C, Pinto Simoes B, Hammans SR, Savage D, Martí R, Chinnery PF, Elhasid R, Gratwohl A, Hirano M. Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. *Brain*. 2015; 138 (Pt 10):2847-58. **IF: 9,196**
103. Castillo N, García-Cadenas I, García O, Barba P, Diaz-Heredia C, Martino R, Azqueta C, Ferrà C, Canals C, Elorza I, Olivé T, Badell I, Sierra J, Duarte R, Valcárcel D, Querol S. Few and nonsevere adverse infusion events using an automated method for diluting and washing before unrelated single cord blood transplantation. *Biol Blood Marrow Transplant*. 2015; 21(4):682-7. **IF: 3,404**
104. Kröger N, Solano C, Wolschke C, Bandini F, Patriarca F, Pini M, Nagler A, Sellner C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Anti-Lymphocyte Globulin for Prevention of Chronic Graft versus Host Disease. *N Engl J Med*. (2015). doi: 10.1056/NEJMoa1506002. [Epub ahead of print]. **IF: 55,873**
105. MARTÍNEZ-CIBRIAN N, MAGNANO L, GUTIÉRREZ-GARCÍA G, ANDRADE X, CORREA JG, SUÁREZ-LLEDÓ M, MARTÍNEZ C, ROVIRA M, CARRERAS E, ROSIÑOL L, DE LARREA CF, CIBEIRA MT, GAYA A, GALLEGRO C, HERNANDO A, CREUS N, BLADÉ J, **URBANO-ISPIZUA Á**, FERNÁNDEZ-AVILÉS F. At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study. *Bone Marrow Transplant*. 2015 Nov 23. doi: 10.1038/bmt.2015.287. [Epub ahead of print]. PMID: 26595072. **IF: 3,466 Q2**.
106. NORIEGA V, MARTÍNEZ-LAPERCHE C, BUCES E, PION M, SÁNCHEZ-HERNÁNDEZ N, MARTÍN-ANTONIO B, GUILLEM V, BOSCH-VIZCAYA A, BENTO L, GONZÁLEZ-RIVERA M, BALSALOBRE P, KWON M, SERRANO D, GAYOSO J, DE LA CÁMARA R, BRUNET S, ROJAS-CONTRERAS R, NIETO JB, MARTÍNEZ C, GÓNZALEZ M, ESPIGADO I, VALLEJO JC, SAMPOL A, JIMÉNEZ-VELASCO A, **URBANO-ISPIZUA A**, SOLANO C, GALLARDO D, DÍEZ-MARTÍN JL, BUÑO I; SPANISH HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL THERAPY GROUP (GETH). The Genotype of the Donor for the (GT)<sub>n</sub> Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. *PLoS One*. 2015 Oct 16;10(10):e0140454. doi: 10.1371/journal.pone.0140454. eCollection 2015. PMID: 26473355. **IF: 3,534. Q1**
107. NOMDEDEU M, LARA-CASTILLO MC, ETXABE A, CORNET-MASANA JM, PRATCORONA M, DÍAZ-BEYÁ M, CALVO X, ROZMAN M, COSTA D, **ESTEVE J**, RISUEÑO RM. Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. *Cancer Cell Int*. 2015 Dec 21;15:122. doi: 10.1186/s12935-015-0272-3. eCollection 2015. PMID: 26696777. **IF: 2,766. Q3**



108. CALVO X, NOMDEDEU M, SANTACRUZ R, MARTÍNEZ N, COSTA D, PEREIRA A, ESTRADA N, XICOY B, **ESTEVE J**, NOMDEDEU B. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. *Leuk Res.* 2015 Jul 23. pii: S0145-2126(15)30324-6. doi: 10.1016/j.leukres.2015.05.017. PubMed PMID: 26354683. **IF. 2.351**
109. DÍAZ-BEYÁ M, BRUNET S, NOMDEDÉU J, CORDEIRO A, TORMO M, ESCODA L, RIBERA JM, ARNAN M, HERAS I, GALLARDO D, BARGAY J, QUEIPO DE LLANO MP, SALAMERO O, MARTÍ JM, SAMPOL A, PEDRO C, HOYOS M, PRATCORONA M, CASTELLANO JJ, NOMDEDEU M, RISUEÑO RM, SIERRA J, MONZÓ M, NAVARRO A, **ESTEVE J**. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute. *Blood Cancer J.* 2015 Oct 2;5:e352. doi: 10.1038/bcj.2015.76. PubMed PMID: 26430723. **IF. 3.467. Q2**
110. DÍAZ-BEYÁ M, BRUNET S, NOMDEDÉU J, PRATCORONA M, CORDEIRO A, GALLARDO D, ESCODA L, TORMO M, HERAS I, RIBERA JM, DUARTE R, DE LLANO MP, BARGAY J, SAMPOL A, NOMDEDEU M, RISUEÑO RM, HOYOS M, SIERRA J, MONZO M, NAVARRO A, **ESTEVE J**; COOPERATIVE AML GROUP CETLAM. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. *Oncotarget.* 2015 Oct 13;6(31):31613-27. doi: 10.18632/oncotarget.5148. PubMed PMID: 26436590. **IF: 6.359. Q1**



### **Headquarters**

C/ Muntaner, 383 3r. 08021  
Barcelona  
Tel. (+34) 93 414 55 66

For any matter concerning this report  
please contact:  
[comunicacio@carrerasresearch.org](mailto:comunicacio@carrerasresearch.org)

The report can also be downloaded  
from:  
<http://www.carrerasresearch.org>

### **Publisher, layout and typesetting**

Josep Carreras Leukaemia Research  
Institute

### **Photography**

Photographic archives of the Josep  
Carreras Leukaemia Foundation and  
the Josep Carreras Leukaemia  
Research Institute

